Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis

OBJECTIVE: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. METHODOLOGY: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Alba, Eduardo, Nuzzolo-Shihadeh, Laura, Aguirre-García, Gloria Mayela, Espinosa-Mora, Jaime, Lecona-Garcia, Juan Diego, Flores-Pérez, Romulo Omar, Mendoza-Garza, Marisela, Camacho-Ortiz, Adrián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253716/
https://www.ncbi.nlm.nih.gov/pubmed/34294593
http://dx.doi.org/10.1016/j.jmii.2021.05.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253716/
https://www.ncbi.nlm.nih.gov/pubmed/34294593
http://dx.doi.org/10.1016/j.jmii.2021.05.009

Ejemplares similares